Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial

• Published in: Clinical therapeutics Vol. 32; no. 2; pp. 365 - 379
• Main Authors: Small, David S., Payne, Christopher D., Kothare, Prajakti, Yuen, Eunice, Natanegara, Fanni, Teng Loh, Mei, Jakubowski, Joseph A., Richard Lachno, D., Li, Ying G., Winters, Kenneth J., Farid, Nagy A., Ni, Lan, Salazar, Daniel E., Tomlin, Molly, Kelly, Ronan
• Format: Journal Article
• Language: English
• Published: Bridgewater, NJ EM Inc USA 01.02.2010; Elsevier; Elsevier Limited
• Subjects: Administration, Oral; Adult; Asian Continental Ancestry Group; Aspirin; Biological and medical sciences; Blood platelets; Blood Platelets - drug effects; Blood Platelets - metabolism; Blood. Blood coagulation. Reticuloendothelial system; Cardiovascular disease; Cell Adhesion Molecules - blood; China - ethnology; clopidogrel; Coronary vessels; Drug therapy; East Asian population; European Continental Ancestry Group; Female; Flow Cytometry; Humans; Internal Medicine; Laboratories; Male; Medical Education; Medical sciences; Microfilament Proteins - blood; Middle Aged; Pharmacodynamics; Pharmacokinetics; Pharmacology. Drug treatments; Phosphoproteins - blood; Piperazines - administration & dosage; Piperazines - adverse effects; Piperazines - pharmacokinetics; platelet aggregation; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - pharmacokinetics; Platelet Function Tests; prasugrel; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2 - blood; Receptors, Purinergic P2Y12; Singapore - epidemiology; Thiophenes - administration & dosage; Thiophenes - adverse effects; Thiophenes - pharmacokinetics; Ticlopidine - administration & dosage; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Vein & artery diseases; Young Adult; Asia; China; Singapore; United Kingdom > UK; United States > US; Indianapolis Indiana; clopidogrel; prasugrel; East Asian population; platelet aggregation; Asiatic; Volunteer; Pharmacotherapy; Aggregation; Hemostasis; Race; Antithrombotic agent; Clinical trial; Human; Drug; Pharmacodynamics; Healthy subject; Single dose; Ethnic group; Biological activity; Antiplatelet agent; Prasugrel; Platelet; Treatment; Platelet function; Clopidogrel; Thienopyridine derivative; Caucasoid; Pharmacokinetics

Background: Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel su...